Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Photodiagnosis and Photodynamic Therapy|March 14, 2025
Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer: Exploratory subject-based analysis in a prospective, single-arm, multicenter phase III trialRikiya Taoka, Hideo Fukuhara, Makito Miyake, et al.
BJU International|August 14, 2013
Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomySeiya Hattori, Takeo Kosaka, Ryuichi Mizuno, et al.
Anticancer Research|April 30, 2022
Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell CarcinomaSuguru Shirotake, Y U Miyama, Yasutaka Baba, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 26, 2025
Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 TrialRikiya Taoka, Hideo Fukuhara, Makito Miyake, et al.
BJUI Compass|February 19, 2024
New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinomaTakafumi Saito, Kent Kanao, Kazuhiro Matsumoto, et al.
Japanese Journal of Clinical Oncology|May 8, 2019
Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapyGo Kaneko, Suguru Shirotake, Koshiro Nishimoto, et al.
The Prostate|August 8, 2019
Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosisMasahito Watanabe, Kent Kanao, Susumu Suzuki, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 8, 2015
Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamicsIkuo Kobayashi, Kazuro Ikawa, Kogenta Nakamura, et al.
Japanese Journal of Clinical Oncology|November 9, 2018
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinomaKeiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, et al.
European Urology Focus|July 21, 2017
External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional StudyNobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, et al.
Pageof 8